BioSpace News Archive

A roundup of last week’s top clinical trial updates and news.

As May gets off to a slow start for the FDA calendar, a few companies have important target action dates.

Shares of Praxis Precision Medicines are falling after the company announced the FDA has placed a clinical hold on the company’s IND Application for its experimental epilepsy drug, Prax-222.

Since its $63 billion acquisition of Allergan in 2019, AbbVie has become one of the leading companies developing therapies for migraine.

Santhera Pharmaceuticals willpublish its annualreport for the year 2021by June 3, 2022 andhold its Annual General Meeting on June 29, 2022.

Genentech, a member of the Roche Group, announced new three-year data from the FIREFISH study, including one-year data from the open label extension, reinforcing the long-term efficacy and safety of Evrysdi® in infants with symptomatic Type 1 spinal muscular atrophy.

Innate Pharma SA announced that AstraZeneca has now dosed the first patient in its Phase 3 clinical trial, PACIFIC-9, evaluating durvalumab in combination with monalizumab or AstraZeneca’s oleclumab in patients with unresectable, Stage III non-small cell lung cancer who have not progressed following definitive platinum-based concurrent chemoradiation therapy.

DUBAI, United Arab Emirates, Remarkable increase in the companion animal ownership and strong growth of development of the veterinary healthcare infrastructure collectively push the sales of companion animal vaccines in global market.

The rising geriatric population and the heightening prevalence of chronic diseases are some important factors that are expected to influence the growth of the clinical chemistry analyzers market during the forecast period of 2020-2030.

Albany NY, United States: Bone cement is a glue-like substance that is infused as an alternative for the missing bone.